#United States #Chronic Rhinosinusitis #Airiver Medical #ESSpand DCB #Brooklyn Park, Minnesota

Airiver Medical's Groundbreaking Clinical Study on Chronic Rhinosinusitis Treatment

In a notable advancement in the field of respiratory health, Airiver Medical has recently treated its first patient with chronic rhinosinusitis (CRS) as part of its pivotal RESTORE-2 clinical trial. The study aims to evaluate the safety and efficacy of the innovative Airiver ESSpand Sinus Drug Coated Balloon (DCB), which could revolutionize treatment for millions suffering from this condition.

Understanding Chronic Rhinosinusitis

Chronic rhinosinusitis is characterized by a persistent inflammatory condition of the nose and paranasal sinuses, lasting for a minimum of three months despite standard treatment efforts. It affects over 14 million adults in the United States alone, with some four million patients often confronting challenges in finding adequate relief through conventional medical therapies. For many, these difficulties lead not only to ongoing discomfort but also to repeated surgical interventions, as symptoms frequently return post-operation.

The Pivotal RESTORE-2 Clinical Trial

The RESTORE-2 trial, led by the esteemed Dr. Andrew Gould, ENT specialist and director of research at Advanced ENT and Allergy in Louisville, Kentucky, aims to enroll up to 300 patients struggling with CRS, including individuals with and without nasal polyps. The study is designed to assess how well the ESSpand DCB can complement endoscopic sinus surgery (ESS). By applying a proprietary paclitaxel drug coating while balloon dilation is performed on narrowed drainage passageways, the DCB potentially promotes long-term symptom relief and reduces the chances of tissue scarring and renarrowing.

Dr. Gould expressed excitement regarding the trial’s initial success, stating, "We're thrilled to have treated the first patient in this important study and very hopeful that this will provide meaningful improvements in outcomes for endoscopic sinus surgery." The success of this trial could lead to significant benefits for healthcare systems and patients alike, including a reduction in the need for additional surgeries or medications like oral steroids and biologics, which can be costly and burdensome.

A Step Towards FDA Submission

Beyond demonstrating the treatment's clinical benefits, the RESTORE-2 study sets the stage for Airiver Medical’s forthcoming regulatory submission to the FDA. If approved, the ESSpand DCB could become a groundbreaking option in the management of chronic rhinosinusitis, offering new hope for patients who currently face limited choices after unsuccessful conventional therapies.

Airiver Medical's CEO, Paul Vajgrt, emphasized the importance of this trial, stating, "This is an important milestone as we're one step closer to providing patients suffering from CRS and physicians with our novel treatment option that has the potential for long-term relief with fewer treatments."

Additional Studies and Future Directions

In parallel with the RESTORE-2 trial, Airiver Medical is also conducting the OXYGEN-RCT clinical study. This separate trial investigates the effectiveness of the investigational Airiver Pulmonary DCB in patients with central airway stenosis—a condition that narrows the airways. Having already treated 21 patients, this study will enroll up to 200, marking another significant step in Airiver Medical's endeavor to innovate respiratory therapies.

The Airiver DCB remains investigational and has not yet gained marketing authorization from the FDA, indicating that it is not available for sale in the United States at this time. However, the prospect for positive change in the realm of treatment for chronic rhinosinusitis and other respiratory issues remains bright, as Airiver Medical continues to push forward with its clinical innovations.

For ongoing updates on Airiver’s clinical trials and advancements in respiratory health technologies, visit Airiver Medical's official website.